International Journal of Neuroscience · 2002 · 48 citations · 30 references
MedicinePharmacologyPsychiatryBone MetabolismNeuropharmacologyPsychopharmacologyBone DisordersBone HealthBone Metabolism DisordersOsteoporosisSchizophrenia PharmacotherapySchizophrenia Spectrum DisordersBone Mineral DensityBone Mineral Density AssessmentBone Mineral Density DeclineBone Mineral Density TestingDrug Effects On Bone DensityDual-energy X-ray Absorptiometry AssessmentLow Bone Mineral Density
There are some reports that classical neuroleptics may lead to osteoporosis or reduced bone mineral density (BMD). However, there is no adequate information about the effects of atypical neuroleptics on BMD. The aim of this study was to measure BMD in schizophrenic patients taking classical and atypical neuroleptics, compared to healthy controls. Seventy-five patients with schizophrenia (40 taking classical neuroleptics [CN], 35 taking atypical neuroleptics [AN]) and 20 healthy controls (HC) were included in the study. Spine (L1-L4) BMD was measured by dual-energy X-ray absorptiometry. ANOVA showed that BMD was higher in HC than AN and CN. In addition, there was a negative correlation between the duration of neuroleptic treatment and BMD and the duration of the illness. These findings suggest that atypical neuroleptics may be safer than the classical neuroleptics in terms of reduced BMD.
30
Decreased Bone Mineral Density in Medicated Psychiatric Patients
Uriel Halbreich, Nathan Rojansky, Steven F. Palter et al. · Psychosomatic Medicine · 1995 · 194 citations
Medicine, Endocrinology, Psychiatry +16
Cigarette smoking, obesity, and bone mass
Charles W. Slemenda, Siu L. Hui, Christopher Longcope et al. · Journal of Bone and Mineral Research · 1989 · 155 citations